06
February 2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
Trademark Approval for
ECOVAXXIN® family in the EU
ECO
Animal Health Group plc (AIM: EAH), a rapidly growing global
animal health company with a portfolio of marketed veterinary
products and a maturing proprietary R&D pipeline, is pleased to
announce that the ECOVAXXIN® trademark has been approved by the
European Union ("EU").
In addition to this EU trademark ECOVAXXIN® has
also been registered in the USA and in the UK, giving extensive
protection in key markets for animal health products.
The registration for ECOVAXXIN® provides
trademark branding for a family of vaccine products. ECOVAXXIN® is
a master trademark and will protect all ECO's forthcoming vaccine
products. Starting in 2025, the Company plans to market its vaccine
products in multiple jurisdictions, with multiple planned launches
over the next ten year period.
The first two planned products to carry the
trademark will be the Company's poultry mycoplasma vaccines,
specifically ECOVAXXIN® MS, a vaccine against Mycoplasma Synoviae,
and ECOVAXXIN® MG, a vaccine against Mycoplasma
Gallisepticum.
The trademark approval supports ECO's strategy
of accelerating growth through the Company's research and
development pipeline. The addition of new vaccines is expected to
significantly support sales and profit growth over the next ten
years.
David Hallas, Chief
Executive Officer of ECO Animal Health Group plc, commented:
"This trademark approval,
complemented by registrations in the USA and the UK, provides broad
protection for the ECOVAXXIN® family,
fortifying our commitment to
advancing growth through innovative vaccine products and supporting
our strategic focus on R&D-driven expansion at ECO Animal
Health Group plc."
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com